Martindale: The Complete Drug Reference 41st Edition

Martindale: The Complete Drug Reference provides unbiased, evaluated information on drugs and medicines in use around the world. It remains the leading international resource, respected for its objectivity, reliability and global coverage, it’s unique offering:

• Includes encyclopaedic facts about drugs and medicines:
• Over 6,600 monographs on drugs and ancillary substances
• Over 200,000 preparations
• Over 60,000 references
• Over 25,000 manufacturers and distributors
• Enables identification of medicines, the local equivalent, and the manufacturer
• Covers herbals, diagnostic agents, radiopharmaceuticals, pharmaceutical excipients, toxins, and poisons
• Evidence-based and extensively referenced

New for the 41st Edition – Over 130 monographs including:

• New antivirals such as fostemsavir and lenacapavir for multi-drug resistant HIV infection and bulevirtide for hepatitis D
• New biological treatments for type 1 diabetes (teplizumab), non-neovascular (dry) age-related macular degeneration (pegcetacoplan), and spinal muscle atrophy type 1 (onasemnogene abeparvovec)
• New class of drugs for migraine management: the calcitonin gene-related peptide (CGRP) receptor antagonists atogepant, rimegepant, ubrogepant, and zavegepant
• New content on management of COVID-19 including a new disease treatment review, COVID-19 infections, new monographs for the antivirals molnupiravir, nirmatrelvir, and remdesivir, and for COVID-19 vaccines, and updates to uses of baricitinib and tocilizumab
• Updated content on malaria and dengue vaccines